Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
151.2 USD | -0.73% | +2.62% | -21.00% |
02/05 | Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed | MT |
02/05 | Transcript : Alnylam Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.00% | 19.27B | |
+22.81% | 47.9B | |
+46.56% | 41.42B | |
-1.88% | 40.7B | |
-6.20% | 28.92B | |
+11.33% | 25.55B | |
-1.43% | 12.15B | |
+30.73% | 12.14B | |
-0.48% | 11.99B | |
+18.47% | 11.64B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- SVB Securities Adjusts Price Target on Alnylam Pharmaceuticals to $98 From $96, Maintains Market Perform Rating